UGT1A1 gene and side effects from certain antibody-drug treatments for advanced breast cancer
Official title: Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
Run by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · NCT07582887 · Data updated 2026-11-12
This project will test whether common UGT1A1 gene variants explain who gets worse side effects from antibody-drug conjugates (sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan) in adults with advanced breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental Academic / other |
| Drugs / interventions | Sacituzumab, Trastuzumab, Datopotamab |
| Locations | 1 site (Granada, Granada) |
| Status | Recruiting |
| Started | July 15, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | March 31, 2027 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT07582887 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with breast cancer who are starting or receiving sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan and who agree to genetic testing are eligible.
✕Probably not a fit
Patients not receiving the specified antibody-drug conjugates or those who decline genetic testing are unlikely to benefit from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects genetic data and clinical toxicity information from adults with locally advanced or metastatic breast cancer who are starting or receiving specified antibody-drug conjugates. Participants provide informed consent for UGT1A1 genotyping and clinicians record adverse events such as neutropenia and severe diarrhea during treatment. Investigators will correlate UGT1A1 variant status (for example *28 and *6) with the frequency and severity of treatment-related toxicities. The goal is to determine whether UGT1A1 variants predict higher risk of adverse effects across these ADCs.
Why it matters
Potential benefit: If successful, the findings could help predict which patients are at higher risk of severe toxicity so clinicians can personalize dosing or choose alternative treatments to reduce harm.
How similar studies have gone: Prior research has linked UGT1A1 variants to increased toxicity with irinotecan and sacituzumab-govitecan, but the impact on trastuzumab-deruxtecan and datopotamab-deruxtecan is less established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 years or older. * Patients diagnosed with breast cancer starting or undergoing treatment with Sacituzumab Govitecan, Trastuzumab Deruxtecan, or Datopotamab Deruxtecan. * Provision of signed informed consent for the genetic study. Exclusion Criteria: * Patients who are ultimately not treated with the specified Antibody-Drug Conjugates. * Refusal to provide informed consent for genetic analysis.
Where it's running
-
Hospital Universitario Clínico San Cecilio
Granada, Granada, Spain Recruiting
Study contacts
- Study coordinator: Isabel Blancas López-Barajas, MD, PhD
- Email: ensayosclinicosom.husc.sspa@juntadeandalucia.es
- Phone: +34 958 023265
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PRT13722 in advanced HR+/HER2- breast cancer
This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.
-
Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure
This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.
-
Telenursing to detect and manage side effects from CDK4/6 inhibitors in breast cancer
This project tests whether scheduled phone or video contacts from trained nurses, added to usual care, help people with breast cancer taking CDK4/6 inhibitors notice and manage side effects earlier and stay on treatment.
-
Generative AI Education Tool for Breast Cancer Care
Researchers are testing an AI-powered teaching tool to help adults with breast cancer understand their care while receiving treatment from UCSF physicians.
-
Pulsed Electric Field Ablation for Metastatic Breast Cancer
This trial tests a one-time pulsed electric field ablation to treat superficial metastatic breast cancer lesions in adults, guided by imaging.
-
Adaptive biomarker-driven therapies for metastatic breast cancer
This trial tests whether matching targeted drug combinations to tumor biomarkers helps people with ER+/HER2- or triple-negative metastatic breast cancer who are starting second-line treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.